VXL — Vaxil Bio Share Price
0.000.00%
Last trade - 00:00- CA$1.37m
- CA$0.36m
- 33
- 31
- 37
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.59 | ||
| Price to Tang. Book | 1.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.26% | ||
| Return on Equity | -41.91% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- October 28th, 2009
- Public Since
- March 2nd, 2011
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 136,978,973
- Address
- 3400 One First Canadian Place,, TORONTO, M5X 1A4
- Web
- Phone
- Auditors
- Zeifman LLP
Upcoming Events for VXL
Similar to VXL
Arch Biopartners
TSX Venture Exchange
biOasis Technologies
TSX Venture Exchange
Ceapro
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
FAQ
What is the Vaxil Bio share price?
As of Today at 19:23 UTC, shares in Vaxil Bio are trading at CA$0.01. This share price information is delayed by 15 minutes.
How has the Vaxil Bio share price performed this year?
Shares in Vaxil Bio last closed at CA$0.01 and the price had moved by -25% over the past 365 days. In terms of relative price strength the Vaxil Bio share price has underperformed the Toronto Stock Exchange 300 Composite Index by -29.52% over the past year.
What are the analyst and broker recommendations for Vaxil Bio?
There is no consensus recommendation for this security.
What is the Vaxil Bio dividend yield?
Vaxil Bio does not currently pay a dividend.
Does Vaxil Bio pay a dividend?
Vaxil Bio does not currently pay a dividend.
When does Vaxil Bio next pay dividends?
Vaxil Bio does not currently pay a dividend.
How do I buy Vaxil Bio shares?
To buy shares in Vaxil Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vaxil Bio?
As of the previous close price of CA$0.01, shares in Vaxil Bio had a market capitalisation of CA$1.37m.
Where are Vaxil Bio shares listed?
Here are the trading details for Vaxil Bio:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: VXL
What kind of share is Vaxil Bio?
Based on an overall assessment of its quality, value and momentum Vaxil Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vaxil Bio share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Vaxil Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxil Bio. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +34.39%.
As of the last closing price of CA$0.01, shares in Vaxil Bio were trading -38.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vaxil Bio PE Ratio?
The Vaxil Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vaxil Bio?
Vaxil Bio's management team is headed by:
- Gadi Levin - CHM
- Ari Kellen - IND
- Shawn Langer - IND